Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2002

View Archived Issues

GSK discusses significant growth opportunities for the future at healthcare conference

Paladin and Pharmacia sign Canadian distribution agreement

AHP highlights next wave of products at investor conference

Anticonvulsants composed of valproic acid and carbonic anhydrase inhibitors

T-bet: an attractive target for antiasthmatic and possibly other drugs

SignalGene's antiangiogenesis drug candidate enters preclinical testing

Advair and Flovent Diskus recommended for approval by FDA committee

PARP inhibitor exerts significant antiinflammatory effects in a number of murine models

MCA gives green light to phase II trial of PTI-801

Immune Network collaborates with AIDS researcher at University of British Columbia

Modified-release NBI-34060 successfully completes phase II trial

Triangle updates its drug development portfolio

Health Canada clears Cytovax to initiate phase I trial of Cytovaxine

Survival data announced from phase II trial of GD-0039 in metastatic renal cancer

Eisai and Neurogenetics extend Alzheimer's disease agreement

IDM and Sanofi-Synthelabo begin cancer immunotherapy collaboration

Novel antibody therapeutic products to be codeveloped by Medarex and Zycos

Benzofuran and benzothiophene derivatives that inhibit 17alpha-hydroxylase/C17-20 lyase

Dual TxA2 and PGD2 antagonists described by scientists at Shionogi

Vitamin D analogues synthesized at Wisconsin Alumni Research Foundation

Dermabond product labeling changed to include protection against common microbes

Nippon Shinyaku reports series of heterocyclic compounds useful in cardiovascular diseases

Isoquinoline derivatives that selectively inhibit protein kinase B disclosed

Kosan researchers design epothilone derivatives with antitumor activity

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...